MYELODYSPLASTIC SYNDROME AND IRON OVERLOAD: RESULTS OF SCREENING EXAMINATION OF 289 PATIENTS
- 作者: Gritsayev S1, Abdulkadyrov K1, Shihbabaeva D1, Gritsaev S.V.1, Abdulkadyrov K.M.1, Shikhbabaeva D.I.1
-
隶属关系:
- 期: 编号 10 (2010)
- 页面: 60-67
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278458
- ID: 278458
如何引用文章
全文:
详细
作者简介
S Gritsayev
K Abdulkadyrov
D Shihbabaeva
Sergey Gritsaev
Kudrat Abdulkadyrov
Dzhariyat Shikhbabaeva
参考
- Абдулкадыров К.М. Гематология. Новейший справочник по гематологии. М.-СПб., 2005. 928 с.
- Steensma DP, Bennet JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006;81:104-130.
- Natchkamp K, Kuendgen A, Hilderbrandt B, et al. Hematological characteristic of patients with myelodysplastic syndromes in the light of WHO 2008 proposals. Blood 2008;112(Abstr.):1658.
- Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008;100:1542-51.
- Cazzola M, Malcovati L. Risk-adapted treatment of myelodysplastic syndromes. Hematology Education. Education program for the 14th congress of the European Hematology Association. 2009;181-87.
- Sekeres MA. Treatment of MDS: something old, something new, something borrowed. Hematology (Am Soc Hematol Educ Program) 2009:656-63.
- Porter JB. Concepts and goals in the management of transfusional iron overload. Am J Hematol 2007;82:1136-39.
- Remacha AF, Arrizabalaga B, Canizo C, et al. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements. Ann Hematol 2010;89:147-54.
- Bullen JJ, Rogers HJ, Spalding PB, et al. Iron and infection: the heart of the matter. FEMS Immunol Med Microbiol 2005;43:325-30.
- Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-603.
- Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 2008;112(Abstr.):640.
- Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52.
- Leitch H, Vickars LM. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron? Hematology (Am Soc Hematol Educ Program) 2009:664-72.
- Rose C, Brechignac, Vassilief D, et al. Does iron chelation therapy improve survival in regulatory transfused lower risk MDS patients? A multicenter study by the GFM. Leuk Res 2010 (available online).
- Schmid M. Iron chelation therapy in MDS: what have we learnt recently? Blood Rev 2009;23(Suppl. 1):S21-S25.
- Armand P, Kim H, Cutler C, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007;109:4586-88.
- Maradei SC, Maiolini A, Azevedo AM, et al. Serrum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 2009;114:1270-75.
- Witte T, Brand R, Biezen A, et al. Allogeneic stem cell transplantation for the patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J haematol 2009;146:627-36.
- Gattermann N. The treatment of secondary hemochromatosis. Dtsch Arztebl Int 2009;106:499-504.
- Witte T. Oral presentation. MDS Iron Forum. Amsterdam. 12 April 2007.
- Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eyes? Blood 2009;114:5251-55.
- Gattermann N. Overview of guidelines on iron chelation in patients with myelodysplastic syndrome. Int J Hematol 2008;88:24-29.
- Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008;83:868-61.
- Sekeres MA. The epidemiology of myelodysplastic syndrome. Hematol Oncol Clin N Am 2010;24:287-94.
- Wu WC, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001;345:1230-36.
- Kao JM, McMillan A, Greenberg P. International MDS risk analysis workshop IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodyspalstic syndromes. Am J Hematol 2008;83:765-70.
- Goldberg S. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Leuk Res 2007;31(Suppl. 3):16-22.
- Oliva EN, Dimitrov BD, Benedetto F, et al. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndromes. Leuk Res 2005;29:1217-19.
- Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodyspalstic syndromes. J Clin Oncol 2007;25:3503-10.
- Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-61.
- Malcovati L. Red blood cell transfusion and iron chelation in patients with myelodyspalstic syndromes. Clinic Lympoma Myeloma Leukem 2009;9(Suppl. 3):305-11.
- Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007;78:487-94.
- Malcovati L, Porta M, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-603.
- Cazzola M, Malcovati L. Myelodysplatic syndromes - coping with ineffective hematopoiesis. N Engl J Med 2005;352:536-38.
- Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1774 patients with transfusion-dependent anemias. Haematologica 2010;95:557-66.
- Anderson GJ. Mechanisms of iron loading and toxicity. Am J Hematol 2007;82:1128-31.
- Cortelezzi A, Cattaneo C, Cristiani S, et al. Non-ransferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol J 2000;1:153-58.
- Piga A, Longo F, Duca L, et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol 2009;84:29-33.